Sodium Methoxide → HCID 86597448, compound
Reaction equation
C([O:9][C@@H:10]1[C@H:14]([O:15]C(=O)C2C=CC=CC=2)[C@@H:13]([CH2:24][O:25]C(=O)C2C=CC=CC=2)[O:12][C@H:11]1[N:34]1[C:38]2=[CH:39][N:40]=[N:41][C:42](=[O:43])[C:37]2=[N:36][CH2:35]1)(=O)C1C=CC=CC=1.C[O-].[Na+]>CO>[C@@H:11]1([N:34]2[C:38]3=[CH:39][N:40]=[N:41][C:42](=[O:43])[C:37]3=[N:36][CH2:35]2)[O:12][C@H:13]([CH2:24][OH:25])[C@@H:14]([OH:15])[C@H:10]1[OH:9]Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Conditions
- Temperature
- 20 °C
Procedure
1-(2,3,5-tri-O-Benzoyl-β-D-ribofuranosyl)imidazo[4,5-d]pyridazin-4-one (555 mg, 0.9 mmol) was added to a solution of sodium methylate (205 mg) in methanol (25 mL) and stirred at 20° C. for 2 hours. The reaction mixture was evaporated to dryness. The residue was dissolved in water and washed with ethyl acetate. The aqueous layer was concentrated under pressure. The crude product was purified on silica gel reverse-phase (C18) using water as eluant to give the title compound (220 mg) as a white powder.
Workup
- customThe reaction mixture was evaporated to dryness
- dissolutionThe residue was dissolved in water
- washwashed with ethyl acetate
- concentrationThe aqueous layer was concentrated under pressure
- customThe crude product was purified on silica gel reverse-phase (C18)
Sources & evidence
- ORD record
- ord-8f0e0a04668048ffb856ed2b086b3f9d
- Source dataset
- uspto-grants-2014_06
- Patent number
- US08742101B2
Reaction notes
Loading…